Chang Chung-ke, Lo Shou-Chen, Wang Yong-Sheng, Hou Ming-Hon
Institute of Biomedical Sciences, Academia Sinica, Nangang, Taipei 11529, Taiwan.
Institute of Genomics and Bioinformatics, National Chung Hsing University, Taichung 40227, Taiwan.
Drug Discov Today. 2016 Apr;21(4):562-72. doi: 10.1016/j.drudis.2015.11.015. Epub 2015 Dec 12.
The advent of severe acute respiratory syndrome (SARS) in the 21st century and the recent outbreak of Middle-East respiratory syndrome (MERS) highlight the importance of coronaviruses (CoVs) as human pathogens, emphasizing the need for development of novel antiviral strategies to combat acute respiratory infections caused by CoVs. Recent studies suggest that nucleocapsid (N) proteins from coronaviruses and other viruses can be useful antiviral drug targets against viral infections. This review aims to provide readers with a concise survey of the structural features of coronavirus N proteins and how these features provide insights into structure-based development of therapeutics against coronaviruses. We will also present our latest results on MERS-CoV N protein and its potential as an antiviral drug target.
21世纪严重急性呼吸综合征(SARS)的出现以及近期中东呼吸综合征(MERS)的爆发凸显了冠状病毒(CoV)作为人类病原体的重要性,强调了开发新型抗病毒策略以对抗由CoV引起的急性呼吸道感染的必要性。最近的研究表明,冠状病毒和其他病毒的核衣壳(N)蛋白可能是对抗病毒感染有用的抗病毒药物靶点。这篇综述旨在为读者简要概述冠状病毒N蛋白的结构特征,以及这些特征如何为基于结构的抗冠状病毒治疗药物开发提供见解。我们还将展示我们关于MERS-CoV N蛋白及其作为抗病毒药物靶点潜力的最新研究结果。